R
Ramakrishna Seethala
Researcher at Bristol-Myers Squibb
Publications - 55
Citations - 2244
Ramakrishna Seethala is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 26, co-authored 55 publications receiving 2177 citations.
Papers
More filters
Journal ArticleDOI
Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor.
Patricia M. Rose,Prabhavathi B. Fernandes,Jean S. Lynch,Scott T. Frazier,Susan M. Fisher,Krishna Kodukula,Bernadette Kienzle,Ramakrishna Seethala +7 more
TL;DR: NPY induced calcium mobilization and inhibited forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells that stably express the Y2 receptors cDNA, indicating that the recombinant Y2 receptor is functionally coupled to second messenger systems.
BookDOI
Handbook of Drug Screening
TL;DR: Key Factors for Successful High-Throughput Screening, John G. Houston Critical Components in high-Through put Screening: Challenges and New Trends, Litao Zhang, Martyn N. Banks, and JohnG.
Journal ArticleDOI
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.
Jacek Ostrowski,Joyce E. Kuhns,John A. Lupisella,Mark C. Manfredi,Blake C. Beehler,Stanley R. Krystek,Yingzhi Bi,Chongqing Sun,Ramakrishna Seethala,Rajasree Golla,Paul G. Sleph,Aberra Fura,Yongmi An,Kevin Kish,John S. Sack,Kasim A. Mookhtiar,Gary J. Grover,Lawrence G. Hamann +17 more
TL;DR: The potent oral activity and tissue selectivity exhibited by BMS-564929 are expected to yield a clinical profile that provides the demonstrated beneficial effects of T in muscle and other tissues with a more favorable safety window.
Journal ArticleDOI
A Fluorescence Polarization Competition Immunoassay for Tyrosine Kinases
Ramakrishna Seethala,Rolf Menzel +1 more
TL;DR: An alternate fluorescence polarization competition immunoassay was designed and evaluated and showed a similar dependence on ATP, Lck enzyme, and the peptide/enolase substrate concentrations with the FP signal inversely proportional to the amount of 32PO4 transferred to the substrate.
Journal ArticleDOI
Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities
Pratik Devasthale,Chen Sean,Jeon Yoon T,Fucheng Qu,Chunning Shao,Wei Wang,Hao Zhang,Michael Cap,Dennis Farrelly,Rajasree Golla,Gary J. Grover,Thomas Harrity,Zhengping Ma,Lisa Moore,Jimmy Ren,Ramakrishna Seethala,Lin Cheng,Paul G. Sleph,Wei Sun,Aaron Tieman,John R. Wetterau,Arthur M. Doweyko,Gamini Chandrasena,Shu Y Chang,W. Griffith Humphreys,Vito G. Sasseville,Scott A. Biller,Denis E. Ryono,Fred Selan,Narayanan Hariharan,Peter T. W. Cheng +30 more
TL;DR: Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPARalpha and PPARgamma.